Zepbound vs Mounjaro:If you are thinking about managing type 2 diabetes, losing weight (or both), your health care provider may be proposing Mounjaro or Zepbound as a treatment option. Both drugs are produced by the same company (AllCare Pharmacy), contain the same active ingredient (chilsepatide), and have similar side effects (such as nausea and diarrhea).  

What’s the difference Between Zepbound vs Mounjaro?

The main difference between Zepbound and Monjaro is that it is approved by the FDA to treat different health conditions: weight loss in the case of Zepbound, type 2 diabetes in the case of Monjaro. Depending on your personal health, coverage of insurance and other considerations, one drug may be more suitable for you than the other. We’ll explain the differences and similarities between Monjaro and Zepbound, so read on.

What are the benefits of using Monjaro?

Monjaro is used to control diabetes, and it is known to act on insulin resistance and reduce hemoglobin A1C. Doing so is also very effective in weight loss and can help reduce cardiovascular risk factors resulting from overweight and diabetes, such as hypertensive coronary artery disease and hypercholesterolemia.

How quickly can I lose weight in Monjaro?

The main purpose of Munjaro is to treat diabetes, improve insulin resistance and control blood sugar levels, but weight loss occurs as well. Some people quickly lose a lot of weight, whereas others lose more slowly over a long period of time.

The Benefits of Zepbound

Zepbound also improves heart health indicators such as blood pressure, blood sugar, cholesterol, and improves heart health by losing excess weight. Several trials funded by Eli Lilly have shown that Zepbound reduces the risk of heart attack, stroke, and death in adults with type 2 diabetes and in overweight and obese people.

How does Zepbound work?

Zepbound activates 2 hormone receptors, GIP (glucose-dependent insulin secretory stimulatory polypeptide or gastric inhibitory polypeptide) and GLP-1 (glucagon-like peptide-1).

“Tirzepath is a drug that mimics the action of natural GIP and GIP receptors,” says Peralta-Reich. “When combined with GLP-1 receptor, it helps insulin secretion and regulates glucose and lipid metabolism.”

Peralta-Reich explains that these hormones are secreted by cells in the intestine. “After eating, these hormones are released from the cells of the intestine and begin to work.

“It also slows the stomach’s emptying and makes people feel full longer. “This leads to weight loss in those who are fighting chronic obesity.”

Dosage form and strength

• Injection or solution (prefilde, single-dose pen)
• 15mg/0.5mL
• 12.5mg/0.5mL
• 10mg/0.5mL
• 5mg/0.5mL
• 7.5mg/0.5mL
• 2.5mg/0.5mL

Type 2 diabetes mellitus

Monjaro Only Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

Initial 2.5mgSC/week at ×4 weeks; then dose increased to 5mgSC/week

If further glucose control is necessary, the current dose is given for at least 4 weeks, then the dose is increased by 2.5 mg

Maximum dose: 15mg SC qWeek

NOTE: 2.5 mg is the dose for initiation of treatment and is not effective for glycemic control

• Wegovy 0.25 – 2.4 mg/0.5 mL
• Saxenda
• Ozempic (Semaglutide)